Skip to main content
BDTX
NASDAQ Life Sciences

Black Diamond Sets Nov. 10 Webcast on Silevertinib Phase 2 Data and FDA-Backed Phase 3 Path

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.95
Mkt Cap
$106.864M
52W Low
$1.6
52W High
$4.94
52W Position info
22% above low
Off High info
61% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BDTX sits 22% above its 52-week low of $1.6.

Summary

Black Diamond will hold an investor webcast Tuesday, November 10, 2026 at 7:30 a.m. ET to present updated Phase 2 results for silevertinib in frontline EGFR-mutant NSCLC, along with FDA feedback that the company says supports a clear Phase 3 path toward potential accelerated approval. The headline is the FDA signal, not the data itself — no efficacy or safety numbers were disclosed in the release, so the actual Phase 2 update lands tomorrow morning. That matters for a micro-cap with a $1.95 stock and a cash runway the company cut to Q2 2027 in its last quarterly report; a credible accelerated-approval route is the difference between needing to raise money on weak terms and having a registrational story to finance against. The company says more than 200 patients have been treated with silevertinib across EGFR-mutant NSCLC and EGFR-altered GBM, and a separate randomized Phase 2 in newly diagnosed EGFRvIII-positive GBM is also running. Watch the 7:30 a.m. ET webcast for the response rate and durability figures that determine whether the Phase 3 plan holds up.

At the time of this announcement, BDTX was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.9M. The 52-week trading range was $1.60 to $4.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BDTX - Latest Insights

BDTX
Nov 10, 2026, 6:31 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.97 info
Change: -$0.0296 (-1%) info
Market Cap: $106.864M info
BDTX
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.00
Real-time Price: $1.97 info
Change: -$0.0296 (-1%) info
Market Cap: $106.864M info
BDTX
Nov 10, 2026, 6:28 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.02
Real-time Price: $1.97 info
Change: -$0.0496 (-2%) info
Market Cap: $106.864M info
BDTX
May 21, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.19
Real-time Price: $1.97 info
Change: -$1.22 (-38%) info
Market Cap: $106.864M info
BDTX
May 21, 2026, 5:13 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.27
Real-time Price: $1.97 info
Change: -$1.30 (-40%) info
Market Cap: $106.864M info